19-221 - Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)Status: open
S1800A, A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)
Treatment for Lung Cancer
S1800A LUNGMAP sub-protocol trial has several investigational treatments that are being tested. The trial prescreening consists of a biomarker test which requires a patient’s tumor sample to be tested for specific genes and proteins. After the biomarker testing result come back the patient will then be assigned to a protocol according to the biomarker testing results. For this sub-study, the patient will be assigned to specific treatment with either the current standard of care treatment or the investigational therapy listed in the sub protocol.
SponsorsThis trial is sponsored by SWOG.
Interested in Clinical Trial?
Providers Associated With This Trial
- Sachin Pai, M.D., M.S.C.I.Medical OncologistProgram Leader of Developmental Therapeutics; Assistant Professor of Interdisciplinary Clinical Oncology
- Moh'd Khushman, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology